Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (symbol: PYXS) is a clinical stage biotechnology company focused on the development of next-generation therapeutics designed to combat difficult-to-treat cancers. The company's mission is to enhance the body's immune response to cancer by targeting specific tumor micro-environments, employing cutting-edge antibody-drug conjugates (ADCs) and immuno-oncology (IO) strategies. Pyxis Oncology aims to improve the quality of life for cancer patients through innovative treatments that directly kill tumor cells and address the pathological factors that enable cancer's proliferation and immune evasion.
Pyxis Oncology is currently developing multiple therapeutic candidates, including PYX-201 and PYX-106, which are in Phase 1 clinical studies targeting a variety of solid tumors. These candidates are designed to be effective both as monotherapies and in combination with existing treatments, providing versatile approaches to cancer therapy. PYX-201 is being evaluated for its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced solid tumors. Similarly, PYX-106 is being assessed in a first-in-human, open-label, multicenter Phase 1 clinical study.
In addition to its robust pipeline, Pyxis Oncology is backed by substantial financial support from institutional investors such as Deep Track Capital, Ridgeback Capital Investments L.P., Blue Owl Healthcare Opportunities, Laurion Capital Management, and StemPoint Capital L.P. Recently, the company secured additional financing to further its research and development efforts, with Leerink Partners and LifeSci Capital serving as placement agents for the private placement.
Pyxis Oncology is committed to translating its preclinical findings into effective clinical treatments. The company has also actively participated in key industry conferences, such as the Society for Immunotherapy of Cancer (SITC) annual meeting, where its research on PYX-201, PYX-106, and other candidates was presented through posters and oral presentations.
Looking forward, Pyxis Oncology has outlined several anticipated milestones, including upcoming financial results for Q4 and the full year 2023, and further updates on their clinical programs. Investors and stakeholders can stay informed through regular updates and detailed news releases.
For more information, visit the Pyxis Oncology website or contact Pamela Connealy, CFO and COO, at ir@pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
What is Pyxis Oncology, Inc.?
What are the company's core products?
What is the focus of Pyxis Oncology's research?
Who are some of Pyxis Oncology's investors?
What recent achievements has Pyxis Oncology announced?
What is the purpose of PYX-201?
How does PYX-106 differ from PYX-201?
What future milestones has Pyxis Oncology outlined?
How can I contact Pyxis Oncology?
Where can I find more information about Pyxis Oncology’s presentations?
